CR20110248A - Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif - Google Patents
Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hifInfo
- Publication number
- CR20110248A CR20110248A CR20110248A CR20110248A CR20110248A CR 20110248 A CR20110248 A CR 20110248A CR 20110248 A CR20110248 A CR 20110248A CR 20110248 A CR20110248 A CR 20110248A CR 20110248 A CR20110248 A CR 20110248A
- Authority
- CR
- Costa Rica
- Prior art keywords
- diseases
- compounds
- arilo
- prevention
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a compuestos de arilo novedosos con sustituyentes heterocíclicos, a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades y a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en particular para el tratamiento y/o la prevención de enfermedades hiperproliferativas y antiangiogénicas y para aquellas enfermedades que surgen de la adaptación metabólica a estados hipóxicos. Tales tratamientos se pueden llevar a cabo como monoterapia o también en combinación con otros medicamentos o medidas terapéuticas adicionales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008057343A DE102008057343A1 (de) | 2008-11-14 | 2008-11-14 | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041242A DE102009041242A1 (de) | 2009-09-11 | 2009-09-11 | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20110248A true CR20110248A (es) | 2011-09-12 |
Family
ID=41445560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20110248A CR20110248A (es) | 2008-11-14 | 2011-05-11 | Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20130196964A1 (es) |
| EP (1) | EP2356113B1 (es) |
| JP (1) | JP5829915B2 (es) |
| KR (1) | KR20110082569A (es) |
| CN (1) | CN102282143A (es) |
| AR (1) | AR074336A1 (es) |
| AU (1) | AU2009316019A1 (es) |
| BR (1) | BRPI0921257A2 (es) |
| CA (1) | CA2743536A1 (es) |
| CL (1) | CL2011001060A1 (es) |
| CO (1) | CO6361923A2 (es) |
| CR (1) | CR20110248A (es) |
| CU (1) | CU24067B1 (es) |
| DK (1) | DK2356113T3 (es) |
| DO (1) | DOP2011000132A (es) |
| EA (1) | EA022271B1 (es) |
| EC (1) | ECSP11011042A (es) |
| ES (1) | ES2538301T3 (es) |
| GT (1) | GT201100118A (es) |
| HN (1) | HN2011001280A (es) |
| HR (1) | HRP20150341T1 (es) |
| IL (1) | IL212142A0 (es) |
| MA (1) | MA32784B1 (es) |
| MX (1) | MX2011005025A (es) |
| MY (1) | MY160004A (es) |
| NZ (1) | NZ592792A (es) |
| PE (1) | PE20110906A1 (es) |
| PL (1) | PL2356113T3 (es) |
| PT (1) | PT2356113E (es) |
| SA (1) | SA109300677B1 (es) |
| SV (1) | SV2011003901A (es) |
| TN (1) | TN2011000234A1 (es) |
| TW (1) | TW201031656A (es) |
| UY (1) | UY32237A (es) |
| WO (1) | WO2010054763A1 (es) |
| ZA (1) | ZA201103476B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009225647C1 (en) * | 2008-03-19 | 2015-11-19 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US10793515B2 (en) | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| EP2523562B1 (en) * | 2010-01-11 | 2019-01-02 | Astraea Therapeutics, LLC | Nicotinic acetylcholine receptor modulators |
| WO2011141326A1 (de) * | 2010-05-08 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung |
| MX2012012905A (es) * | 2010-05-08 | 2012-12-17 | Bayer Ip Gmbh | Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas. |
| AR088020A1 (es) | 2010-06-30 | 2014-05-07 | Ironwood Pharmaceuticals Inc | Compuestos heterociclicos como estimuladores de sgc |
| CA2817319A1 (en) | 2010-11-09 | 2012-05-18 | Ironwood Pharmaceuticals, Inc. | Triazole derivatives as sgc stimulators |
| UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| CN104144925A (zh) | 2011-10-17 | 2014-11-12 | 拜耳知识产权有限责任公司 | 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮 |
| CN106117194A (zh) | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 |
| JP2015508809A (ja) * | 2012-02-28 | 2015-03-23 | ピラマル エンタープライジーズ リミテッド | Ｇｐｒアゴニストとしてのフェニルアルカン酸誘導体 |
| AU2013286860B2 (en) | 2012-07-02 | 2017-10-26 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
| EP2888253A4 (en) | 2012-08-24 | 2016-01-06 | Univ Texas | HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES |
| US20140073634A1 (en) * | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| CN104736535B (zh) | 2012-08-24 | 2017-12-19 | 德州大学系统董事会 | 用于治疗疾病的hif活性的杂环调节剂 |
| WO2014114928A1 (en) * | 2013-01-23 | 2014-07-31 | Astrazeneca Ab | Chemical compounds |
| DK3110420T3 (da) | 2014-02-25 | 2019-05-13 | Board Of Regents Univ Of Texas System | Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme |
| AU2017289318A1 (en) | 2016-06-30 | 2018-11-29 | Basilea Pharmaceutica International AG | Mitochondrial inhibitors for the treatment of proliferation disorders |
| JP6972144B2 (ja) * | 2017-02-06 | 2021-11-24 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | １−アリール−１−トリフルオロメチルシクロプロパンを合成するための新規な方法 |
| TW201927302A (zh) | 2017-10-12 | 2019-07-16 | 瑞士商巴塞利亞藥業國際股份有限公司 | 用於治療增殖障礙之線粒體抑制劑 |
| US10953036B2 (en) | 2017-11-20 | 2021-03-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods of modulating HIF-2A to improve muscle generation and repair |
| TW201927767A (zh) | 2017-12-14 | 2019-07-16 | 瑞士商巴塞利亞藥業國際股份有限公司 | 用於治療增生性障礙之線粒體抑制劑 |
| CN112630366A (zh) * | 2020-12-18 | 2021-04-09 | 卓和药业集团有限公司 | 甲钴胺分散片含量的高效液相色谱检测方法 |
| US20230101768A1 (en) * | 2021-08-13 | 2023-03-30 | The Board Of Regents Of The University Of Texas System | Method to treat manganese toxicity and manganese-induced parkinsonism in humans |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060110741A (ko) * | 2003-06-30 | 2006-10-25 | 히프 바이오 인크 | 화합물, 조성물 및 방법 |
| CA2586420A1 (en) * | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| ITMI20042475A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di derivati tiazolidinonici come agenti terapeutici |
| US8071795B2 (en) * | 2005-08-25 | 2011-12-06 | Emory University | HIF inhibitors |
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| US8796253B2 (en) * | 2007-05-18 | 2014-08-05 | Bayer Intellectual Property Gmbh | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| DE102008057344A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
-
2009
- 2009-10-31 ES ES09744351.9T patent/ES2538301T3/es active Active
- 2009-10-31 MY MYPI2011002091A patent/MY160004A/en unknown
- 2009-10-31 KR KR1020117010966A patent/KR20110082569A/ko not_active Application Discontinuation
- 2009-10-31 CN CN2009801545968A patent/CN102282143A/zh active Pending
- 2009-10-31 WO PCT/EP2009/007806 patent/WO2010054763A1/de active Application Filing
- 2009-10-31 PE PE2011000986A patent/PE20110906A1/es not_active Application Discontinuation
- 2009-10-31 CA CA2743536A patent/CA2743536A1/en not_active Abandoned
- 2009-10-31 AU AU2009316019A patent/AU2009316019A1/en not_active Abandoned
- 2009-10-31 PT PT97443519T patent/PT2356113E/pt unknown
- 2009-10-31 MX MX2011005025A patent/MX2011005025A/es active IP Right Grant
- 2009-10-31 EA EA201100778A patent/EA022271B1/ru not_active IP Right Cessation
- 2009-10-31 US US13/129,407 patent/US20130196964A1/en not_active Abandoned
- 2009-10-31 EP EP09744351.9A patent/EP2356113B1/de active Active
- 2009-10-31 DK DK09744351T patent/DK2356113T3/en active
- 2009-10-31 NZ NZ592792A patent/NZ592792A/xx not_active IP Right Cessation
- 2009-10-31 CU CU2011000102A patent/CU24067B1/es not_active IP Right Cessation
- 2009-10-31 JP JP2011535902A patent/JP5829915B2/ja not_active Expired - Fee Related
- 2009-10-31 BR BRPI0921257A patent/BRPI0921257A2/pt not_active IP Right Cessation
- 2009-10-31 PL PL09744351T patent/PL2356113T3/pl unknown
- 2009-11-11 UY UY0001032237A patent/UY32237A/es not_active Application Discontinuation
- 2009-11-11 AR ARP090104356A patent/AR074336A1/es not_active Application Discontinuation
- 2009-11-12 TW TW098138333A patent/TW201031656A/zh unknown
- 2009-11-14 SA SA109300677A patent/SA109300677B1/ar unknown
-
2011
- 2011-04-05 IL IL212142A patent/IL212142A0/en unknown
- 2011-05-10 CL CL2011001060A patent/CL2011001060A1/es unknown
- 2011-05-11 MA MA33832A patent/MA32784B1/fr unknown
- 2011-05-11 CR CR20110248A patent/CR20110248A/es unknown
- 2011-05-11 EC EC2011011042A patent/ECSP11011042A/es unknown
- 2011-05-11 GT GT201100118A patent/GT201100118A/es unknown
- 2011-05-11 DO DO2011000132A patent/DOP2011000132A/es unknown
- 2011-05-11 SV SV2011003901A patent/SV2011003901A/es unknown
- 2011-05-12 CO CO11058530A patent/CO6361923A2/es active IP Right Grant
- 2011-05-12 HN HN2011001280A patent/HN2011001280A/es unknown
- 2011-05-12 TN TN2011000234A patent/TN2011000234A1/fr unknown
- 2011-05-12 ZA ZA2011/03476A patent/ZA201103476B/en unknown
-
2015
- 2015-03-26 HR HRP20150341TT patent/HRP20150341T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6361923A2 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
| UY32236A (es) | Compuestos de arilo sustituidos y su uso | |
| NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
| EA201201648A1 (ru) | Стимуляторы sgc | |
| CU20140141A7 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| CU20120157A7 (es) | Heterociclilbencilpirazoles sustituidos y uso de los mismos | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| BR112015003729A8 (pt) | Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| BR112013020159A2 (pt) | método para inibir células tumorais de hamartoma | |
| PH12015500746A1 (en) | Benzamides | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| BR112012028652A2 (pt) | hidroxialquilbenzilpirazois e seu uso | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| UA103784C2 (ru) | Гетероциклически замещенные арильные соединения как ингибиторы гиф | |
| MX2014001271A (es) | Tratamiento de diabetes de tipo 2 con fty720. | |
| UA94869C2 (ru) | Применение липофлавона в качестве средства для лечения острой черепно-мозговой травмы | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives |